Comparison of Effects of Injectable Contraceptives (Cyclofem and Depot Medroxyprogesterone Acetate) on Short Time Side Effects, Acceptability and Continuation Rates

Document Type : Original Article


1 Ph.D. Student of Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Lecturer of Midwifery, Pregnancy Health Research Center, School of Nursing and Midwifery, Zahedan University of Medical Sciences, Zahedan, Iran.

3 Associate Professor, Department of Biostatistics, School of Para-medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Introduction: The most common reason for discontinue depot medroxyprogesterone acetate in first year of using is correlated with menstruation disorders and weight gain. The aim of this study was determining and comparing the effects of cyclofem and depot medroxyprogesterone acetate on short time side effects, acceptability and continuation rates in women.
Methods: This clinical trial was conducted on 68 women who used contraceptive injections in Zahedan, Iran, 2010. During a period of 90 days, women registered bleeding events and possible side effects in the form of daily menstrual bleeding and side effects. User-satisfaction questionnaires were administered at 3 months after the first injection or earlier if a client decided to discontinue from the study. Data were analyzed using SPSS software version 18 and chi-square, Fisher exact test, t-test and Mann-Whitney tests. P value less than 0.05 was considered significant.
Results: The continuation rate for cyclofem was 52.9% compared with 79.4% for Depo-Provera. Nausea and mean of weight gain was showed significant differences in two groups (p=0.01). Although user satisfaction was not statistically significant difference (p=0.7) but main reasons in two groups for non- accepting was different.
Conclusion: Menstruation disturbances were main reason for non- accepting of Depo-Provera and difficult to come for visits was main reason for discontinuing of cyclofem.


  1. Fathizadeh N, Abdi F, Savabi M. A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD. Iran J Nurs Midwifwey Res 2011 Fall;16(4):304-8.
  2. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol 2009 Aug;114(2 Pt 1):279-84.
  3. Prabhakaran S. Self-administration of injectable contraceptives. Contraception 2008 May;77(5):315-7.
  4. Haji Kazemy E, Nikpoor S, Haghani H. [Study of reasons for discontinuation of DMPA in referred womens to Iran university medical and health centers] [Article in Persian]. Razi J Med Sci 2003;9(31):515-20.
  5. Bachmann G, Korner P. Bleeding pattern with non-oral hormonal contraceptives: a review of the literature. Contraception 2009 Apr;79(4):247-58.
  6. Hubacher D, Lopez L, Steiner M, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparison. Contraception 2009 Aug;80(2):113-8.
  7. Torgrimson BN, Meendering JR, Kaplan PF, Minson CT. DMPA and endothelial function prior to and after acute oral, vaginal, and transdermal estradiol treatment. Hypertension 2011 Apr;57(4):819-24.
  8. Beksinska ME, Smit JA, Kleinschmidt I, Milford C, Farley TM. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception. Contraception 2010 Jan;81(1):30-4.
  9. Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception 2006 June;73(6):584-7.
  10. Thurman A, Kimble T, Hall P, Schwartz JL, Archer DF. Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. Contraception 2013 June;87(6):738-43.
  11. Yazdanpanah M, Eslami M, Andalib P, Motlaq ME, Jadidi N, Nakhaee N. Acceptability and side effects of Cyclofem© once-a-month injectable contraceptive in Kerman, Iran J Reprod Med 2010;8(4):191-6.
  12. Botolotti de Mello Jacobucci MS, Guazzelli CA, Barbieri M, Araujo FF, Moron AF. Bleeding patterns of adolescents using a combination contraceptive injection for 1 year. Contraception 2006 June;73(6):594-7.
  13. Szarewski A, Moeller C. Women’s perceptions about reducing the frequency of monthly bleeding: results from a multinational survey. Open Access J Contraception 2013 May;4:29-37.
  14. O’Flynn N. Menstrual symptoms: the importance of social factors in women’s experiences. Br J Gen Pract 2006 Dec;56(533):950-7.
  15. Snow R, Hardy E, Kneuper E, Hebling EM, Hall G. Women’s responses to menses and nonbleeding intervals in the USA, Brazil and Germany. Contraception 2007 Jul 1;76(1):23-9. 17.
  16. Bitzer J, Serrani M, Lahav A. Women’s attitudes towards heavy menstrual bleeding, and their impact on quality of life. Open Access J Contraception 2013 Apr;4:21-8.
  17. Ruminjo JK, Sekadde-Kigondu CB, Karanja JG, Rivera R, Nasution M, Nutley T. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception 2005 Aug;72(2):138-45.
  18. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced byfertility regulating methods. world health organization special programme of research, development and research training in human reproduction. Contraception 1986 Sep;34(3):253-60.
  19. Homayounfar N, Sehati Shafaee F, Mardi A, Amani F, Jafarzadeh H. Continuation of injectable form of DMPA usage in Ardabil Health Centers 2005] [Article in Persian]. J Ardabil Univ Med Sci 2007;7(4):418- 22.
  20. Homayounfar N, Sehati Shafaee F, Amani F. [Factors affecting continuation rate of Depotmedroxyprogesterone acetate injectable contraceptive among Tabrize women] [Article in Persian]. J Ardabil Univ Med Sci 2010;11(4):11-7.
  21. Bulent Tiras M, Noyan V, Fener N, Guner H, Yildirim M, Darney P. Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters. Contraception 2001 Mar;63(3):151-3.
  22. Simbar M, Zham H, Ramezani F, Hashemi Z, Fraser I. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. J Fam Plann Reprod Health Care 2007;33(4):271-6.
  23. Kamalifard M, Mohammad Alizadeh S, Sadeghi H, Hasanzadeh R. Comparison of Continuation Rates and Reasons for Discontinuation of Cyclofem and Depo- Provera in Health Houses of East Azarbaijan, Iran, 2009. Nurs Midwifery J 2010 Summer;5(18):22-30.
  24. Canto de cetina TE, Luna MO, Cetina Canto JA, Bassol S. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception 2004 Feb;69(2):115-9.
  25. Guazzelli CA, Jacobucci MS, Barbieri M, Araujo FF, Moron AF. Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects. Contraception 2007 Jul;76(1):45-8.
  26. Goli S, Soleymani B, Goli M, Goodarzi M. [The comparison between bleeding pattern, body weight, and blood pressure variations during the use of depot medroxyprogesterone acetate (DMPA) and cyclofem] [Article in Persian]. Arak Med Univ J 2012;15(62) 66-74.